Workflow
Canopy Growth(CGC) - 2025 Q4 - Annual Report
CGCCanopy Growth(CGC)2025-05-30 10:45

Financial Performance - Canopy Growth reported net revenue of CAD 268.995 million for the year ended March 31, 2025, a decrease of 9% from CAD 297.146 million in 2024 [449]. - The gross margin percentage improved to 30% in fiscal 2025, up from 27% in fiscal 2024, reflecting strategic changes and cost savings initiatives [458]. - Net loss from continuing operations increased to CAD 604.138 million in fiscal 2025, compared to CAD 483.682 million in 2024, representing a 25% increase in losses [449]. - Canadian adult-use cannabis revenue decreased by 15% to CAD 78.828 million in fiscal 2025, primarily due to lower sales volumes and increased price competition [451][453]. - Canadian medical cannabis revenue increased by 16% to CAD 77.032 million in fiscal 2025, driven by a higher average order size and a larger product assortment [451][454]. - International markets cannabis revenue decreased by 4% to CAD 39.734 million in fiscal 2025, attributed to declines in the Australian market and U.S. CBD business [451][455]. - Revenue from Storz & Bickel increased by 4% to CAD 73.401 million in fiscal 2025, supported by strong sales growth in Germany and the UK [451][456]. - The divestiture of This Works on December 18, 2023, resulted in a complete revenue loss from this segment, which was CAD 21.256 million in fiscal 2024 [451][457]. - Cost of goods sold decreased by 12% to CAD 189.484 million in fiscal 2025, contributing to the improved gross margin [458]. - Canopy Growth's weighted average number of outstanding common shares increased to 107,553,729 in fiscal 2025, up from 74,787,521 in fiscal 2024 [449]. Operating Expenses - Total operating expenses decreased to 196.7millioninfiscal2025,down36196.7 million in fiscal 2025, down 36% from 309.6 million in fiscal 2024 [465]. - General and administrative expenses were 65.1millioninfiscal2025,a2865.1 million in fiscal 2025, a 28% decrease from 90.3 million in fiscal 2024 [467]. - Sales and marketing expenses dropped to 60.9millioninfiscal2025,down2060.9 million in fiscal 2025, down 20% from 76.1 million in fiscal 2024 [468]. - The company incurred acquisition-related costs of 19.5millioninfiscal2025,downfrom19.5 million in fiscal 2025, down from 34.8 million in fiscal 2024, reflecting ongoing restructuring efforts [469]. - Total restructuring, asset impairments, and related costs in fiscal 2025 amounted to 33.2million,downfrom33.2 million, down from 65.0 million in fiscal 2024 [482][484]. Cash Flow and Liquidity - Cash used in operating activities for fiscal 2025 was 165.8million,adecreasefrom165.8 million, a decrease from 282.0 million in fiscal 2024, primarily due to reduced operating losses and lower cash interest payments [547]. - Cash used in investing activities totaled 47.8millioninfiscal2025,with47.8 million in fiscal 2025, with 10.8 million for property, plant, and equipment improvements and 95.3millionforstrategicinvestments,includingtheacquisitionofAcreagesdebt[549].Cashprovidedbyfinancingactivitieswas95.3 million for strategic investments, including the acquisition of Acreage's debt [549]. - Cash provided by financing activities was 148.7 million in fiscal 2025, driven by 385.4millionfromcommonshareissuancesunderATMPrograms,offsetby385.4 million from common share issuances under ATM Programs, offset by 289.0 million in long-term debt repayments [552]. - Free cash flow for fiscal 2025 was an outflow of 176.6million,animprovementfromanoutflowof176.6 million, an improvement from an outflow of 231.9 million in fiscal 2024, reflecting decreased cash used in operating activities [557]. - The company reported a net decrease in cash and cash equivalents of 56.5millionforfiscal2025,comparedtoadecreaseof56.5 million for fiscal 2025, compared to a decrease of 506.7 million in fiscal 2024 [545]. Debt and Financing - Total debt outstanding as of March 31, 2025, was 304.1million,downfrom304.1 million, down from 597.2 million as of March 31, 2024, representing a decrease of approximately 49% [559]. - The total principal amount owing as of March 31, 2025, was 315.5million,areductionfrom315.5 million, a reduction from 622.0 million at March 31, 2024, indicating a decrease of about 49% [559]. - The company entered into a Credit Agreement providing for a Credit Facility in the aggregate principal amount of US750.0milliononMarch18,2021[560].ThecompanymadeanOptionalPrepaymentresultinginanaggregateprincipalreductionof750.0 million on March 18, 2021 [560]. - The company made an Optional Prepayment resulting in an aggregate principal reduction of 143.9 million (US100.0million)foracashpaymentof100.0 million) for a cash payment of 140.3 million (US97.5million)onMarch31,2025[571].ThecompanyrepurchasedadditionaloutstandingprincipalamountsundertheCreditFacilityresultinginanaggregateprincipalreductionof97.5 million) on March 31, 2025 [571]. - The company repurchased additional outstanding principal amounts under the Credit Facility resulting in an aggregate principal reduction of 73.3 million (US54.5million)foracashpaymentof54.5 million) for a cash payment of 69.6 million (US51.8million)onAugust11,2023,andSeptember14,2023[564].ImpairmentsandRestructuringThecompanyrecognizedagoodwillimpairmentlosstotaling51.8 million) on August 11, 2023, and September 14, 2023 [564]. Impairments and Restructuring - The company recognized a goodwill impairment loss totaling 1.7 billion for the cannabis operations reporting unit in the first quarter of fiscal 2023 [603]. - The company recognized a non-cash impairment of divestiture-related assets and employee restructuring costs contributing to the total restructuring costs [482]. - Impairment charges in fiscal 2024 totaled 79.5million,including79.5 million, including 42.1 million in goodwill impairment losses related to the Storz & Bickel reporting unit [527]. - The company recognized fair value changes on Canopy USA related assets resulting in increased expenses of 237.3millioninfiscal2025[490].StrategicInitiativesThecompanycompletedtheacquisitionofAcreage,owning100237.3 million in fiscal 2025 [490]. Strategic Initiatives - The company completed the acquisition of Acreage, owning 100% of the issued and outstanding shares, with 5,888,291 common shares issued to former shareholders of Acreage [432]. - The company has received EU-GMP certification at its Kincardine facility, enabling the export of certified medical cannabis to European markets [415]. - The company maintains agreements to supply all Canadian provinces and territories with adult-use products through established retail distribution systems [419]. - The company has developed a compassionate pricing program offering eligible low-income patients a 20% discount on regular prices of medical cannabis [419]. - The company has established an at-the-market equity program allowing it to issue and sell up to US250 million of Canopy Shares [429].